Blog
Category: Parkinsons Disease
Harnessing Neuroimaging in Parkinson’s Disease Clinical Trials: Best Practices and Emerging Standards
As clinical research in Parkinson’s Disease (PD) continues to evolve, neuroimaging has become a cornerstone in trial design, patient selection, and therapeutic evaluation. Across the industry, sponsors and imaging partners are adopting increasingly sophisticated imaging strategies to enhance data quality, regulatory compliance, and scientific insight.
The New Research Developments Driving Precision Care in Parkinson’s Disease
Parkinson’s disease (PD) research is advancing rapidly, driven by innovations in neuroimaging, biomarker science, and therapeutic development. The field is moving beyond symptom management toward biologically grounded strategies for early diagnosis, disease staging, and modification. Biomarker-Driven Staging: The NSD-ISS Framework A major shift is underway in how PD is diagnosed and staged.
Discussing research multi-biomarker advances in Alzheimer’s Disease at ADPD 2025
This week we will be at the ADPD 2025 International Conference talking about some of our latest biomarker research. Specifically, we are presenting an AI-based approach to differentiate different types of dementia from magnetic resonance imaging (MRI).